徐立忠博士目前担任上海博槿生物科技有限公司总裁兼首席科学官，全面负责肿瘤、炎症与自身免疫病、心血管与代谢性疾病等治疗领域的创新性生物药研发，职责范围涵盖靶点的选择直至候选药物在临床上的概念证明。得益于20余年在美、中学术界与制药业的丰富工作经验, 徐博士具有国际视野, 深入了解多个疾病领域的前沿研发状况、抗体筛选与优化技术、新药开发流程及审批法规要求, 成功主导和参与过美国IND和中国NDA申报工作。
徐博士拥有北京大学细胞生物学学士及哈佛大学生物化学博士学位，在斯坦福大学医学院进行博士后研究期间获得国际著名的Damon Runyon癌症研究基金会博士后奖学金, 在伊利诺大学香槟分校担任免疫学助理教授期间获得NIH R01科研经费。2006年10月加入诺华上海研发中心, 任资深研究员, 对转化医学部的建立与运营起了关键作用, 参与了一系列IND临床开发计划及临床试验方案的设计, 并运用生物标志物方法来评估临床试验中新药的药效动力学与疗效。2011年9月加入葛兰素史克公司, 任生物(制)药副总监, 负责抗体与重组蛋白类新药的设计、筛选与优化。2014年5月加入上海仁会生物制药股份有限公司，任首席科学官。在其领导之下，一系列抗体新药发现项目得以启动，多个项目进展良好；此外，徐博士还组织了2型糖尿病新药谊生泰新适应症(肥胖)拓展工作，完成了IND申报所需的药理、毒理研究，设计了一个随机、双盲、安慰剂对照、序贯平行分组、多剂量爬坡的临床试验方案以评估谊生泰在超重和肥胖人群中的安全性、耐受性、体内代谢及初步疗效，并于2016年7月成功地从美国FDA获得临床批件。徐博士于2017年初与上海博威生物医药有限公司总裁兼CEO王少雄博士共同创立博槿生物科技。
John L. Xu, Ph.D.
President CSO
Mab-Legend Biotech Co., Ltd.
Dr. John Xu is currently the President and CSO of Mab-Legend Biotech. In this role, he is responsible for biologic medicine R&D in the oncology, inflammation and autoimmunity, and cardiovascular and metabolic disease areas, from target selection through Proof-of-Concept clinical studies. Before co-founding Mab-Legend, Dr. Xu worked at Novartis as Sr. Investigator, Translational Medicine; at GSK as Associate Director, Biologics Drug Discovery; and at Shanghai Benemae Pharmaceutical Corp. as CSO and Head of Pharmaceutical R&D.
Dr. Xu has more than 25 years of working experiences in biomedical research and pharmaceutical industry. At GSK, he was in charge of the screening and optimization of therapeutic antibody and other recombinant proteins using a variety of technology platforms. At Novartis, he contributed to the development of Clinical Development Plan for a number of investigational new drugs and applied biomarker strategy to assess the pharmacodynamics and efficacy of these NMEs in global trials. At Benemae, he led company-wide efforts to conduct IND-enabling studies for a GLP-1 receptor agonist, designed the protocol for a phase 1, randomized, double-blind, placebo-controlled, sequential parallel group, multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics and early efficacy of the drug in overweight and obese subjects for chronic weight management, and received the “safe-to-proceed” feedback from the US FDA.
Dr. Xu received his B.S. degree in Cell Biology from Peking University and Ph.D. degree in Biochemistry from Harvard University. He was a recipient of Damon Runyon Cancer Research Foundation Fellowship when he was a post-doctoral fellow in Immunology at Stanford University School of Medicine and of NIH R01 Grant when he was an Assistant Professor at the University of Illinois at Urbana-Champaign.
